Ambrilia Biopharma Showcases ICPD Analysis Results

Ambrila to present new clinical data on its lead HIV drug
PPL-100 at the XVI International Aids Conference

Montreal, August 14, 2006 – Ambrilia Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today that it will be presenting the latest clinical findings on its lead HIV protease inhibitor (PI), PPL-100, a prodrug of PL-100, at the XVI International AIDS Conference (Toronto, Canada).

An oral presentation by Dr. Jinzi J. Wu, Vice-President, Preclinical and Basic Research of Ambrilia, will be made on Thursday, August 17 ^th, at 3:00 p.m. EST in Session Room 7 (Oral Abstract Session: HIV Drug Development) of the Metro Toronto Convention Center. The presentation entitled “PL-100, a novel protease inhibitor with a high genetic barrier” will discuss PPL-100’s genetic barrier, the final safety and pharmacokinetic data of the first-in-man, single-dose escalation studies, and results of the population pharmacokinetic modeling and target attainment analyses conducted by scientists at the Institute of Clinical Pharmacodynamics (ICPD), Ordway Research Institute, Albany, NY.

According to Dr. Paul G. Ambrose, Director of ICPD, “such analyses are becoming the standard for dose selection so as to maximize patient safety and efficacy”. As per Dr. George L. Drusano, Co-Director of Ordway Research Institute, Albany, NY, “these data suggest that PPL-100 could be a first-line, once-daily oral PI, without the need of ritonavir boosting, for both PI-naïve and experienced patients infected with highly resistant strains.”

About Protease Inhibitors

Protease Inhibitors (PIs) such as PPL-100, are a key component to the current HIV standard of care, the Highly Active Anti-Retroviral Treatment (HAART) consisting of a cocktail of reverse transcriptase inhibitors and PIs. Unfortunately, most PIs are associated with side effects, a high pill burden, and as it is the case with all anti-HIV drugs, the development of viral resistance. In addition, the majority of PIs are administered in combination with a small dose of ritonavir (a PI) which is used to increase (“boost”) the amount of available drug in the system but which at the same time increases the adverse events. More than ever, there is a pressing need for safer, more convenient and effective PIs.

About ICPD

The ICPD serves as a center for translational science collaboration to the world. We help pharmaceutical and biotechnology companies develop more effective and safer drugs through advanced methods of pharmacokinetic and pharmacodynamic system analysis. Our general contact information is as follows:

Telephone: (518) 429-2600
Info@ICPD.com

About Ambrilia Biopharma

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative and proprietary early- to mid-stage therapeutics in the fields of oncology and infectious diseases. Ambrilia’s product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, SPC3). Ambrilia’s head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company’s web site: www.ambrilia.com

Ambrilia Biopharma Inc.
Julie M. Thibodeau
Director, Communications
jthibodeau@ambrilia.com
ir@ambrilia.com
Tel.: (514) 751-2003 ext 235
www.ambrilia.com

Forward-looking statements-This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company’s filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia’s products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia’s views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements.